BioSpace News Archive

Galera Therapeutics, Inc. announced final results from its Phase 1/2 pilot trial of its dismutase mimetic, GC4419, versus placebo, in patients with unresectable or borderline resectable locally advanced pancreatic cancer, who are undergoing stereotactic body radiation therapy.

Longboard Pharmaceuticals, Inc. announced that the Company successfully completed the multiple ascending dose portion of a Phase 1 clinical trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating doses of LP352, an oral, centrally acting, next-generation 5-HT2c receptor superagonist, in healthy volunteers.

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced that the Company will participate in three investor conferences in September.

atHeart Medical, a medical device company dedicated to establishing the new standard of care for closure of atrial septal defects, announced the appointment of Andrew Cleeland to the company’s Board of Directors.

Virios Therapeutics, Inc., a clinical-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, announced that the United States Patent and Trademark Office has granted Virios Therapeutics patent exclusivity on its valacyclovir-celecoxib combination drug candidate to 2033.

MOMA Therapeutics, a biopharmaceutical company discovering the next generation of precision medicines by targeting molecular machines that underlie human disease, announced that Semi Trotto has been appointed as the company’s chief people and experience officer.

Antibe Therapeutics Inc., a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for a wide range of inflammatory conditions, announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually on September 13 - 15.

Bristol Myers Squibb (NYSE:BMY) will announce results for the third quarter of 2021 on Wednesday, October 27, 2021. During a conference call at 8 a.m. ET on October 27, 2021, company executives will review financial results and address inquiries from investors and analysts.

ReForm Biologics , Inc. today announced the appointment of Jeffrey S. Hackman as President and Chief Executive Officer (CEO).

Appili Therapeutics Inc. today announced the results from its annual general meeting of shareholders held on Tuesday, September 7, 2021.